2023-11-10T15:40:29-06:00 2022-12-31 410746749 CLIFTONLARSONALLEN LLP TWO INTERNATIONAL PLACE 22ND FLOOR BOSTON MA 02110 990 2022-01-01 521224577 BIOTECHNOLOGY INNOVATION ORGANIZATION BIOT 2029629200 1201 NEW YORK AVE NW NO 1300 WASHINGTON DC 20005 STEPHEN JASKO CFO & EVP OF BUSN DEVELOPMENT 2029629200 2023-11-09 1 STEPHEN JASKO XXX-XX-XXXX 0 LAURA J KENNEY P00202198 6177170831 2023-11-09 2 AAL1 IAL1 2022 2023-04-26 12:10:37Z X RACHEL KING 1201 NEW YORK AVE NW NO 1300 WASHINGTON DC 20005 112257445 0 X WWW.BIO.ORG X 1981 DC BIO IS THE WORLD'S LARGEST ADVOCACY ASSOCIATION REPRESENTING APPROXIMATELY 1,000 MEMBER COMPANIES, STATE BIOTECHNOLOGY GROUPS, ACADEMIC AND RESEARCH INSTITUTIONS, PATIENT GROUPS, AND RELATED ORGANIZATIONS ACROSS THE UNITED STATES AND IN 30+ COUNTRIES. BIO IS FOUNDED ON THE PRINCIPLE THAT POLICY MUST NURTURE INNOVATION IN THE LIFE SCIENCES TO OVERCOME CHALLENGES IN HEALTH CARE, AGRICULTURE, INDUSTRY, AND THE ENVIRONMENT. BIO'S EFFORTS INCLUDE ADVOCACY AND POLICY EFFORTS FOCUSED ON THE INNOVATIVE HEALTH OF THE SECTOR ALONG WITH CONVENING EVENTS AND OFFERING OTHER MEMBER SERVICES. 102 102 175 102 59273 15505 154941 874632 52920414 77932917 6180523 3416988 21654962 20960638 80910840 103185175 2103465 711285 0 0 34982444 33487118 0 0 0 42972209 52145707 80058118 86344110 852722 16841065 113666319 124412600 69410674 73648403 44255645 50764197 X THE BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO) REPRESENTS APPROXIMATELY 1,000 COMPANIES AND ORGANIZATIONS IN WASHINGTON DC, STATE CAPITALS, AND INTERNATIONAL FORA. BIO IS FOUNDED ON THE PRINCIPLE THAT POLICY MUST NURTURE INNOVATION IN THE LIFE SCIENCES TO OVERCOME CHALLENGES IN HEALTH CARE, AGRICULTURE, INDUSTRY, AND THE ENVIRONMENT. OUR MEMBERS REPRESENT COMPANIES OFFERING A SPECTRUM OF BIOTECHNOLOGY APPLICATIONS ACROSS MAJOR SECTORS OF THE ECONOMY. BIO MEMBERS ALSO INCLUDE UNIVERSITIES, NONPROFITS, PATIENT GROUPS, AND OTHER ORGANIZATIONS THAT PLAY AN IMPORTANT ROLE IN THE FUTURE OF THE LIFE SCIENCES. BIO'S ACTIVITIES ARE BROKEN DOWN INTO TWO PROGRAMS - ADVOCACY AND SERVICES. 0 0 ADVOCACY: BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO)'S ADVOCACY EFFORTS REFLECT THE PRIORITIES IDENTIFIED BY THE BIO BOARD OF DIRECTORS AND THE FOUR SECTION GOVERNING BOARDS.THE BOARD OF DIRECTORS FOCUSES ON ISSUES OF IMPORTANCE TO ALL BIO MEMBERS, REGARDLESS OF THEIR SIZE OR TECHNOLOGY. THESE CROSS-CUTTING ADVOCACY ACCOMPLISHMENTS FOR THE YEAR ARE LISTED BELOW: - SAFEGUARDED AND ADVANCED INTELLECTUAL PROPERTY PROTECTIONS, DOMESTICALLY AND INTERNATIONALLY.- FOSTERED A DIALOGUE ABOUT BIOETHICS AND PROACTIVELY ADVANCED THE SOCIALLY RESPONSIBLE USE OF BIOTECHNOLOGY.- PROMOTED INVESTMENT IN GOVERNMENT AND ACADEMIC RESEARCH.- EXPANDED OUTREACH TO FOREIGN GOVERNMENTS AND INTERNATIONAL ENTITIES TO EDUCATE ON POLICY ISSUES OF IMPORTANCE TO THE BIOTECHNOLOGY INDUSTRY AND TO IMPROVE THE INVESTMENT AND REGULATORY CLIMATE FOR BIOTECH PRODUCTS.THE HEALTH SECTION ADVOCACY ACCOMPLISHMENTS: - PROMOTED HEALTHCARE POLICIES THAT RECOGNIZE BOTH THE PROMISE AND VALUE OF INNOVATION.- ADVOCATED FOR A SAFE AND PREDICTABLE REGULATORY ENVIRONMENT FOR VALUE-BASED PAYMENT ARRANGEMENTS FOR DRUGS AND BIOLOGICS.- ENHANCED AND PROTECTED PATIENT ACCESS TO INNOVATIVE THERAPIES AND PROMOTED THE NEED FOR GREATER NONDISCRIMINATION ENFORCEMENT AGAINST INSURANCE BENEFIT DESIGNS.- ADVOCATED FOR BIOSIMILARS POLICIES THAT PROTECT PATIENT SAFETY, PROMOTE BIOMEDICAL INNOVATION, AND ADVANCE THE SCIENCE-BASED REVIEW AND APPROVAL OF BIOSIMILARS AND INTERCHANGEABLE BIOLOGICAL PRODUCTS.- PROMOTED THE VALUE OF U.S. GOVERNMENT INVESTMENTS IN PROGRAMS THAT IMPROVE ACCESS TO IMMUNIZATIONS AND FOSTER VACCINE INNOVATION, STRENGTHENED OUR ABILITY TO RESPOND TO BIOTERROR THREATS OR EMERGING INFECTIOUS DISEASES, AND ENCOURAGED DEVELOPMENT OF NEW PRODUCTS TO FIGHT ANTIMICROBIAL RESISTANCE (AMR).- INFLUENCED IMPROVEMENTS TO THE INTERNATIONAL ENVIRONMENT FOR BIOMEDICAL INNOVATION AND GLOBAL PUBLIC HEALTH PREPAREDNESS.- ADVOCATED FOR THE MODERNIZATION OF THE CLINICAL DEVELOPMENT PARADIGM.THE EMERGING COMPANIES SECTION ADVOCACY ACCOMPLISHMENTS: - ADVANCED THE INTEREST OF EMERGING COMPANIES IN CAPITAL FORMATION AND FINANCIAL SERVICES POLICY.- ADVOCATED FOR FISCAL POLICIES SUPPORTING INNOVATIVE EMERGING COMPANIES AND INVESTMENT IN GROUNDBREAKING R&D; ENHANCED THE VOICE OF PRE-REVENUE, R&D-INTENSIVE BUSINESSES- ADVOCATED FOR THE REMOVAL OF BURDENSOME FINANCIAL REPORTING REGULATIONS ON EMERGING COMPANIES.THE FOOD & AGRICULTURE SECTION ADVOCACY ACCOMPLISHMENTS: - WORKED WITH THE ADMINISTRATION AND CONGRESS TO ADVANCE IMPROVEMENTS TO THE U.S. AND GLOBAL REGULATORY SYSTEMS FOR AG-BIOTECH PRODUCTS. - WORKED WITH MEMBERS OF THE AGRICULTURAL VALUE CHAIN TO ADDRESS TRADE ISSUES IN AGRICULTURAL EXPORT MARKETS SUCH AS CHINA AND EUROPE. - ADVOCATED IN LEGISLATURES AND COURTS TO PRESERVE THE RIGHTS OF FARMERS TO PLANT GENETICALLY ENGINEERED CROPS. THE INDUSTRIAL & ENVIRONMENTAL SECTION ADVOCACY ACCOMPLISHMENTS: - SUPPORTED A RENEWABLE CHEMICALS REPORT.- ADVOCATED FOR EPA TO TREAT ALL SUSTAINABLY SOURCED BIOMASS AS ELIGIBLE MEASURES FOR EMISSIONS REDUCTION CREDIT (ERC) GENERATION. - ADVOCATED REGARDING THE IMPLEMENTATION OF THE TOXIC SUBSTANCES CONTROL ACT (TSCA) AS AMENDED BY CONGRESS, AS WELL AS ISSUES RELATING TO THE NATIONAL BIOENGINEERED FOOD DISCLOSURE ACT.- ENGAGED WITH THE ADMINISTRATION'S REVIEW OF THE COORDINATED FRAMEWORK FOR BIOTECHNOLOGY, INCLUDING WITH RESPECT TO THE REGULATION OF GENETICALLY ENGINEERED (GE) ALGAE. SERVICES: BIO'S SERVICES INCLUDE CONFERENCES AND ACTIVITIES THAT BRING ADVOCACY ACCOMPLISHMENTS LISTED BELOW:- SAFEGUARDED AND ADVANCED INTELLECTUAL PROPERTY PROTECTIONS, DOMESTICALLY AND INTERNATIONALLY.- FOSTERED A DIALOGUE ABOUT BIOETHICS AND PROACTIVELY ADVANCED THE SOCIALLY RESPONSIBLE USE OF BIOTECHNOLOGY.- PROMOTED INVESTMENT IN GOVERNMENT AND ACADEMIC RESEARCH.- BROUGHT TOGETHER INDUSTRY STAKEHOLDERS AND INVESTORS FOR EVENTS RANGING FROM THE BIO INTERNATIONAL CONVENTION TO CONFERENCES FOR BUSINES DEVELOPMENT EXECUTIVES.THE BIO INTERNATIONAL CONVENTION ATTRACTS THE MOST INFLUENTIAL BIOTECH AND PHARMA ATTENDEES FROM 73 COUNTRIES AND 47 U.S. STATES, AS WELL AS THE DISTRICT OF COLUMBIA, PUERTO RICO AND THE US VIRGIN ISLANDS AND OFFERS PROFESSIONAL AND BUSINESS DEVELOPMENT OPPORTUNITIES. THE NET INCOME FROM THE CONVENTION SUPPORTS OUR ADVOCACY, PUBLIC OUTREACH, AND OTHER MEMBER SERVICE ACTIVITIES.THE KEY ELEMENTS OF THE BIO INTERNATIONAL CONVENTION ARE EDUCATIONAL PROGRAMMING, EXHIBITION, THE BIO BUSINESS FORUM, AND NETWORKING EVENTS. THESE ELEMENTS PROVIDE AN OPPORTUNITY FOR BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES, ACADEMIC RESEARCH INSTITUTIONS, AND INVESTORS FROM AROUND THE WORLD TO LEARN ABOUT RECENT SCIENTIFIC AND POLICY DEVELOPMENTS, AND SCHEDULE ONE-ON-ONE MEETINGS TO DISCUSS POTENTIAL BUSINESS OPPORTUNITIES. THE BIO BUSINESS FORUM AT THE CONVENTION HOSTS TENS OF THOUSANDS OF PARTNERING MEETINGS AMONG A FEW THOUSAND COMPANIES, ALONG WITH A COUPLE HUNDRED COMPANY PRESENTATIONS. THE CONVENTION HOSTS HUNDREDS OF SPEAKERS, AND OVER A THOUSAND EXHIBITIONS WITH INTERNATIONAL, REGIONAL AND STATE PAVILIONS (AND A NUMBER OF PRODUCT FOCUS ZONES).BEYOND THE CONVENTION, BIO HOSTS OR CO-HOSTS A NUMBER OF NATIONAL AND INTERNATIONAL CONFERENCES THAT PROVIDE VENUES FOR MEMBER AND NON-MEMBER COMPANIES TO PRESENT NEW DATA, MEET WITH FELLOW BIOTECH COMPANIES, AND ATTRACT FUNDING FROM INVESTORS AND OTHER ORGANIZATIONS. 0 1 0 1 0 0 0 0 0 1 0 0 1 1 0 1 0 0 0 1 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 159 0 1 175 1 1 1 1 IN 0 0 1 0 0 1 0 X 102 102 1 0 0 0 1 1 0 1 1 0 0 0 1 1 1 1 1 1 1 0 X STEPHEN JASKO 2029629200 1201 NEW YORK AVE NW STE 1300 WASHINGTON DC 20005 X RACHEL K KING PRES CEO EMERITUS BOARD MEM (SINCE NOV 2022) 40.00 X X 241642 0 5929 JULIE LOUISE GERBERDING ASSOC VICE CHAIR/SECY (UNTIL 5/2022) 2.00 X X 0 0 0 PAUL J HASTINGS CHAIR 2.00 X X 0 0 0 JEREMY M LEVIN IMMEDIATE PAST CHAIR 2.00 X X 0 0 0 ELIZABETH LEWIS ASSOCIATE VICE CHAIR & SECRETARY 2.00 X X 0 0 0 BRADFORD A ZAKES TREASURER 2.00 X X 0 0 0 JOHN F CROWLEY EMERGING COMPANIES SECTION CHAIR 2.00 X X 0 0 0 JENNIFER HOLMGREN AGRICULTURE & ENVIRONMENT VICE CHAIR 2.00 X X 0 0 0 TED W LOVE HEALTH SECTION VICE CHAIR 2.00 X X 0 0 0 ERIKA SMITH EMERGING COMPANIES SECT. VICE CHAIR 2.00 X X 0 0 0 SUE WASHER EMERGING COMPANIES SECT VC & SECY 2.00 X X 0 0 0 SYLVIA WULF AGRICULTURE & ENVIRONMENT SECT CHAIR 2.00 X X 0 0 0 JILL ZULLO UNTIL JAN 2022 AGRICULTURE & ENVIRONMENT CO-CHAIR 2.00 X X 0 0 0 ANGELA CARISA AILLONI DIRECTOR 2.00 X 0 0 0 STEVE ALBERS DIRECTOR 2.00 X 0 0 0 BONNIE ANDERSON DIRECTOR (UNTIL JANUARY 2022) 2.00 X 0 0 0 STUART A ARBUCKLE DIRECTOR 2.00 X 0 0 0 MARTIN BABLER DIRECTOR 2.00 X 0 0 0 DOUG BERVEN DIRECTOR 2.00 X 0 0 0 SULAGNA BHATTACHARYA DIRECTOR 2.00 X 0 0 0 JEAN-JACQUES BIENAIME DIRECTOR 2.00 X 0 0 0 FRITZ BITTENBENDER DIRECTOR 2.00 X 0 0 0 CHRISTOPHER BOERNER DIRECTOR 2.00 X 0 0 0 CARRIE L BOURDOW DIRECTOR 2.00 X 0 0 0 CARINE BOUSTANY DIRECTOR 2.00 X 0 0 0 STEPHEN BRADY DIRECTOR 2.00 X 0 0 0 VICTOR BULTO DIRECTOR 2.00 X 0 0 0 EMMANUEL CAEYMAEX DIRECTOR 2.00 X 0 0 0 PABLO J CAGNONI DIRECTOR 2.00 X 0 0 0 KAY CHANDLER DIRECTOR 2.00 X 0 0 0 IVAN CHEUNG DIRECTOR 2.00 X 0 0 0 GIACOMO CHIESI DIRECTOR 2.00 X 0 0 0 JEFFREY L CLELAND DIRECTOR 2.00 X 0 0 0 RON COHEN DIRECTOR 2.00 X 0 0 0 GRACE E COLON DIRECTOR 2.00 X 0 0 0 BRUCE C COZADD DIRECTOR 2.00 X 0 0 0 ROGER CRYSTAL DIRECTOR 2.00 X 0 0 0 DOUGLAS DOERFLER DIRECTOR 2.00 X 0 0 0 ERIC M DUBE DIRECTOR 2.00 X 0 0 0 MARC DUNOYER DIRECTOR 2.00 X 0 0 0 MARK ENYEDY DIRECTOR 2.00 X 0 0 0 BARRY P FLANNELLY DIRECTOR 2.00 X 0 0 0 ALEXANDRIA FORBES DIRECTOR 2.00 X 0 0 0 KAYE FOSTER DIRECTOR 2.00 X 0 0 0 CEDRIC FRANCOIS DIRECTOR 2.00 X 0 0 0 JOHN GLASSPOOL DIRECTOR 2.00 X 0 0 0 JENNIFER GOOD DIRECTOR 2.00 X 0 0 0 KEVIN C GORMAN DIRECTOR 2.00 X 0 0 0 YVONNE GREENSTREET DIRECTOR 2.00 X 0 0 0 PATRICK GRUBER DIRECTOR 2.00 X 0 0 0 CHIRFI GUINDO DIRECTOR (UNTIL JULY 2022) 2.00 X 0 0 0 SEBASTIAN GUTH DIRECTOR 2.00 X 0 0 0 STEVEN HARR DIRECTOR 2.00 X 0 0 0 RACHEL HAURWITZ DIRECTOR 2.00 X 0 0 0 CHRISTOPHER HEALEY DIRECTOR 2.00 X 0 0 0 MIKE HUCKMAN DIRECTOR 2.00 X 0 0 0 ELIZABETH JEFFORDS DIRECTOR 2.00 X 0 0 0 PATRIK JONSSON DIRECTOR 2.00 X 0 0 0 ALEX KARNAL DIRECTOR 2.00 X 0 0 0 DANIEL KEIL DIRECTOR (UNTIL FEBRUARY 2022) 2.00 X 0 0 0 DAVID KETTNER DIRECTOR 2.00 X 0 0 0 SCOTT KOENIG DIRECTOR 2.00 X 0 0 0 SAMARTH KULKARNI DIRECTOR 2.00 X 0 0 0 JOSEPH J LAROSA DIRECTOR 2.00 X 0 0 0 CHRIS LEIBMAN DIRECTOR 2.00 X 0 0 0 JOHN LEPORE DIRECTOR (UNTIL NOVEMBER 2022) 2.00 X 0 0 0 SANDY MACRAE DIRECTOR 2.00 X 0 0 0 GAIL MADERIS DIRECTOR 2.00 X 0 0 0 AAMIR MALIK DIRECTOR 2.00 X 0 0 0 ANTHONY MANCINI DIRECTOR 2.00 X 0 0 0 JOHN MARAGANORE DIRECTOR 2.00 X 0 0 0 MAYA MARTINEZ-DAVIS DIRECTOR 2.00 X 0 0 0 SHARON MATES DIRECTOR 2.00 X 0 0 0 THOMAS P MATHERS DIRECTOR 2.00 X 0 0 0 JOHN MELO DIRECTOR (UNTIL DECEMBER 2022) 2.00 X 0 0 0 SHEILA ANN MIKHAIL DIRECTOR 2.00 X 0 0 0 BOB MORE DIRECTOR (UNTIL JUNE 2022) 2.00 X 0 0 0 ROCCO MORELLI DIRECTOR 2.00 X 0 0 0 MICHAEL M MORRISSEY DIRECTOR 2.00 X 0 0 0 MIKE NARACHI DIRECTOR 2.00 X 0 0 0 AMIR NASHAT DIRECTOR 2.00 X 0 0 0 WILLIAM J NEWELL DIRECTOR 2.00 X 0 0 0 ANDREW OBENSHAIN DIRECTOR 2.00 X 0 0 0 JANNIE OOSTHUIZEN DIRECTOR 2.00 X 0 0 0 JULIA OWENS DIRECTOR 2.00 X 0 0 0 JOHN V OYLER DIRECTOR 2.00 X 0 0 0 ADELENE Q PERKINS DIRECTOR 2.00 X 0 0 0 MARK PLATT DIRECTOR (UNTIL NOVEMBER 2022) 2.00 X 0 0 0 RICHARD POPS DIRECTOR 2.00 X 0 0 0 MARK PRUZANSKI DIRECTOR 2.00 X 0 0 0 SOFIE QIAO DIRECTOR 2.00 X 0 0 0 MIKE G RAAB DIRECTOR 2.00 X 0 0 0 ANNA RATH DIRECTOR 2.00 X 0 0 0 ELENA RICE DIRECTOR 2.00 X 0 0 0 HOWARD W ROBIN DIRECTOR (UNTIL DECEMBER 2022) 2.00 X 0 0 0 MICHAEL J RUGGIERO DIRECTOR 2.00 X 0 0 0 JAMES SAPIRSTEIN DIRECTOR 2.00 X 0 0 0 CHRISTOPHE SCHILLING DIRECTOR 2.00 X 0 0 0 CHRISTI SHAW DIRECTOR 2.00 X 0 0 0 JEFFREY SHERMAN DIRECTOR 2.00 X 0 0 0 BILL SIBOLD DIRECTOR 2.00 X 0 0 0 NANCY SIMONIAN DIRECTOR 2.00 X 0 0 0 DUANE J SIMPSON DIRECTOR 2.00 X 0 0 0 ELAINE K SORG DIRECTOR 2.00 X 0 0 0 EDDIE J SULLIVAN DIRECTOR 2.00 X 0 0 0 IAN THOMPSON DIRECTOR 2.00 X 0 0 0 LINDA TROLINDER DIRECTOR 2.00 X 0 0 0 MARK C TRUDEAU DIRECTOR (UNTIL JULY 2022) 2.00 X 0 0 0 OLIVER WALKER DIRECTOR (UNTIL MARCH 2022) 2.00 X 0 0 0 HENRIK WAREBORN DIRECTOR (UNTIL NOVEMBER 2022) 2.00 X 0 0 0 NEIL K WARMA DIRECTOR 2.00 X 0 0 0 FRANK WATANABE DIRECTOR 2.00 X 0 0 0 SCOTT WHITE DIRECTOR 2.00 X 0 0 0 RICK E WINNINGHAM DIRECTOR 2.00 X 0 0 0 ROGER WYSE DIRECTOR 2.00 X 0 0 0 JOHN YOUNG DIRECTOR (UNTIL JANUARY 2022) 2.00 X 0 0 0 MICHELLE MCMURRY-HEATH PRESIDENT AND CEO (UNTIL NOV 2022) 40.00 X 2345095 0 298316 STEPHEN JASKO CHIEF FINANCIAL OFFICER, EVP BUSINESS DEVELOPMENT 40.00 X 658466 0 66647 RICHARD MASTERS CHIEF PUBLIC AFFAIRS & MARKETING OFFICER 40.00 X 748964 0 79248 NICHOLAS SHIPLEY CHIEF ADVOCACY OFFICER 40.00 X 747313 0 71539 ELIZABETH ESHAM CHIEF SCIENCE OFFICER 40.00 X 677602 0 53234 PETER MCHUGH CHIEF LEGAL OFFICER 40.00 X 610444 0 81585 JOSEPH DAMOND THRU JAN 2022 DEPUTY CHIEF POLICY OFFICER AND EVP IN'L AFFAIRS 40.00 X 600225 0 5370 6629751 0 661868 100 0 1 0 ARENTFOX SCHIFF LLP 1717 K ST NW WASHINGTON DC 200065344 LEGAL SERVICES 677194 THE SAMANTHA SAULT AGENCY LLC 2039 NEW HAMPSHIRE AVE NW SUITE 10 WASHINGTON DC 20009 EDITORIAL SUPPORT 621818 MARKSTEIN CONSULTING LLC 1801 5TH AVE NORTH SUITE 200 BIRMINGHAM AL 35203 COMMUNICATIONS & MARKETING 596081 M LLC 217 CHURCH ST PHILADELPHIA PA 19106 CREATIVE STRATEGY DIRECTION 576207 O'KEEFE COMMUNICATIONS LLC 2 BETHESDA METRO CENTER SUITE 310 BETHESDA MD 20814 EVENT STAGING & LABOR 482261 37 874632 874632 CONFERENCE / MEETING REVENUE 541800 37819268 37759995 59273 MEMBERSHIP DUES 900003 36288173 36288173 SPECIAL INITIATIVES 900003 2609145 2609145 CBI LOBBYING FUND 900003 1059504 1059504 OTHER PROGRAM SERVICES 900003 156827 156827 77932917 1361299 1361299 20939661 20939661 11127959 9072270 2055689 2055689 2055689 INSURANCE CLAIMS REVENUE 524298 20977 20977 20977 103185175 77873644 59273 24377626 711285 7291621 20702321 45118 3748622 1699436 1326410 107163 5629204 51879 7356092 1536484 2175449 1760018 4883154 1433368 11945360 8509408 724072 273185 DUES & SUBSCRIPTIONS 2358330 SPECIAL INITIATIVE EXPE 1758217 TAXES PAID 317914 86344110 8880294 35460368 4248582 1220372 5336669 7153037 3636584 3329669 13546522 1847635 11058896 11698887 52911446 44601716 27593848 20948551 113666319 124412600 18109640 17018984 10845666 16155091 40455368 40474328 69410674 73648403 X 44255645 50764197 44255645 50764197 113666319 124412600 16841065 -10332513 0 X 0 1 X 1 0 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 0 1 36288173 12078789 -2540091 9538698 12700860 -3162162 9609554 426638 9182916 2662532 146561 2515971 1274436 1274436 0 11698887 RIGHT OF USE ASSET - OPERATING 20948551 20948551 LEASE LIABILITY - OPERATING 40256849 BIO-PAC 217479 40474328 92800783 -10332513 -10332513 103133296 51879 51879 103185175 86292231 0 86292231 51879 51879 86344110 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 PROGRAM SERVICES CONFERENCES, ADVOCACY AND EDUCATION 26115 0 0 0 0 0 0 26115 0 26115 0 0 0 0 0 0 PART I, LINE 2: THERE WERE NO GRANTS OUTSIDE THE U.S. IN 2022. THE ORGANIZATION USES THE ACCRUAL METHOD OF ACCOUNTING TO REPORT EXPENDITURES FOR ACTIVITIES OUTSIDE OF THE U.S. PART III ACCOUNTING METHOD: 1 ALLIANCE FOR AGING RESEARCH 1700 K STREET NW SUITE 740 WASHINGTON DC 20006 541379174 501(C)(3) 20000 0 SPONSORSHIP AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC 555 11TH STREET SUITE 300 WASHINGTON DC 20004 522340031 501(C)(3) 25000 0 SPONSORSHIP AUTOIMMUNE ASSOCIATION 19176 HALL RD SUITE 130 CLINTON TWP MI 48038 383027574 501(C)(3) 10500 0 SPONSORSHIP BIOKANSAS 11005 W 60TH ST SUITE 310 SHAWNEE KS 66203 200013564 501(C)(3) 8000 0 SPONSORSHIP BIONJ INC 1255 WHITEHORSE-MERCERVILLE RD BUILDING B - SUITE 514 TRENTON NJ 08619 223284393 501(C)(6) 35000 0 SPONSORSHIP CALIFORNIA LIFE SCIENCES ASSOCIATION 9605 SCRANTON ROAD SUITE 120 SAN DIEGO CA 92121 473226523 501(C)(3) 18000 0 SPONSORSHIP CENTER FOR FOOD INTEGRITY 2900 NE BROOKTREE LANE SUITE 200 GLADSTONE MO 64119 204662713 501(C)(4) 25000 0 SPONSORSHIP COALITION OF SKIN DISEASES 4301 CONNECTICUT AVE NW SUITE 404 WASHINGTON DC 20008 208948050 501(C)(3) 7500 0 SPONSORSHIP COLORADO BIOSCIENCE ASSOCIATION 600 GRANT STREET SUITE 306 DENVER CO 80203 841363258 501(C)(6) 6000 0 SPONSORSHIP EPILEPSY FOUNDATION 3540 CRAIN HIGHWAY SUITE 675 BOWIE MD 20716 520856660 501(C)(3) 8000 0 SUPPORT EVERYLIFE FOUNDATION FOR RARE DISEASES 1012 14TH ST NW SUITE 500 WASHINGTON DC 20005 264614274 501(C)(3) 25000 0 CONTRIBUTION FRIENDS OF CANCER RESEARCH 1800 M ST NW SUITE 1050 SOUTH TOWER WASHINGTON DC 20036 521983273 501(C)(3) 10000 0 SPONSORSHIP GEORGE MASON UNIVERSITY FOUNDATION INC 4400 UNIVERSITY DRIVE MSN 1A3 ARLINGTON VA 22030 541603842 501(C)(3) 10000 0 DONATION GEORGIA BIO 999 PEACHTREE AVE NE ATLANTA GA 303093996 581849665 501(C)(3) 10850 0 SPONSORSHIP GLOBAL LIVER INSTITUTE INC 4323 WESTOVER PLACE NW WASHINGTON DC 20016 464687212 501(C)(3) 7500 0 DONATION HIV AND HEPATITIS POLICY INSTITUTE 1602B BELMONT ST NW WASHINGTON DC 200096546 844147678 501(C)(3) 7500 0 SUPPORT HM&C CENTER STAGE LLC 233 PENNSYLVANIA AVENUE SE SECOND FLOOR WASHINGTON DC 20003 261582812 501(C)(3) 10000 0 SPONSORSHIP IBIO 400 N ABERDEEN ST SUITE 900 CHICAGO IL 60642 364225980 501(C)(3) 15000 0 SPONSORSHIP LIFE SCIENCE WASHINGTON 1551 EASTLAKE AVE E SUITE 300 SEATTLE WA 98102 911453398 501(C)(6) 7500 0 SUPPORT LIFE SCIENCES PENNSYLVANIA 650 EAST SWEDESFORD RD SUITE 190 WAYNE PA 19087 251621500 501(C)(6) 11010 0 SPONSORSHIP LUPUS FOUNDATION OF AMERICA INC 2121 K STREET NW SUITE 200 WASHINGTON DC 20037 431131436 501(C)(3) 7500 0 SPONSORSHIP MARYLAND TECHNOLOGY COUNCIL INC 9841 WASHINGTONIAN BLVD SUITE 200 GAITHERSBURG MD 20878 204950778 501(C)(6) 11250 0 SUPPORT MASSACHUSETTS BIOTECHNOLOGY COUNCIL INC 700 TECHNOLOGY SQUARE 5TH FLOOR CAMBRIDGE MA 02139 222693047 501(C)(6) 7500 0 SPONSORSHIP MONTANA BIOSCIENCE ALLIANCE P O BOX 1773 BILLINGS MT 59106 201647600 501(C)(3) 7500 0 SUPPORT NATIONAL HEALTH COUNCIL 1730 M STREET NW SUITE 500 WASHINGTON DC 200364561 131624107 501(C)(3) 70000 0 SPONSORSHIP NEW YORK BIOTECHNOLOGY ASSOC 25 HEALTH SCIENCES DR SUITE 203 STONY BROOK NY 11790 113026494 501(C)(3) 12500 0 SPONSORSHIP POPVOX FOUNDATION 541 WILEY PARKER ROAD JACKSON TN 38305 861884678 501(C)(3) 15000 0 SPONSORSHIP PREVENT CANCER FOUNDATION 1600 DUKE ST SUITE 500 ALEXANDRIA VA 22314 521429544 501(C)(3) 6500 0 SPONSORSHIP REPUBLICAN GOVERNORS ASSOCIATION 1747 PENNSYLVANIA AVE NW SUITE 250 WASHINGTON DC 20006 113655877 527 15000 0 SPONSORSHIP SICK CELLS 4512 RIVER DRIVE LISLE IL 60532 813481633 501(C)(3) 10000 0 SPONSORSHIP TEXAS HEALTHCARE & BIOSCIENCE 815 BRAZOS ST SUITE 310 AUSTIN TX 78701 760501034 501(C)(6) 13500 0 SPONSORSHIP THE BRIGHAM AND WOMEN'S HOSPITAL INC 75 FRANCIS ST MAIL CODE 300 FENWAY R BOSTON MA 02115 042312909 501(C)(3) 10000 0 SPONSORSHIP THE PLENARY CO 886A DE HARO ST SAN FRANCISCO CA 94107 472796683 501(C)(3) 10000 0 SUPPORT WOMEN IN BIO INC PO BOX 97900 PITTSBURGH PA 15227 030458239 501(C)(3) 15000 0 SPONSORSHIP WOMEN OF COLOR IN PHARMA PO BOX 6172 SOMERSET NJ 08875 813871261 501(C)(6) 10000 0 SPONSORSHIP 25 10 PART I, LINE 2: BIO RELIES ON THE REQUIRED QUALIFICATIONS OF THE GRANT RECIPIENTS TO PROVIDE ASSURANCE OF PROPER USAGE. IN SOME CASES, BIO PERSONNEL ATTEND EVENTS AND RECEIVE ACKNOWLEDGEMENTS RELATED TO THE FUNDS GRANTED. X 1 1 X X X X 1 1 0 MICHELLE MCMURRY-HEATH PRESIDENT AND CEO (UNTIL NOV 2022) 1267245 0 1075000 0 2850 0 265497 0 32819 0 2643411 0 0 0 RICHARD MASTERS CHIEF PUBLIC AFFAIRS & MARKETING OFF 574364 0 171000 0 3600 0 40047 0 39201 0 828212 0 0 0 NICHOLAS SHIPLEY CHIEF ADVOCACY OFFICER 568713 0 175000 0 3600 0 34963 0 36576 0 818852 0 0 0 ELIZABETH ESHAM CHIEF SCIENCE OFFICER 530002 0 144000 0 3600 0 38335 0 14899 0 730836 0 0 0 STEPHEN JASKO CHIEF FINANCIAL OFFICER, EVP BUSINES 519866 0 135000 0 3600 0 40047 0 26600 0 725113 0 0 0 PETER MCHUGH CHIEF LEGAL OFFICER 471844 0 135000 0 3600 0 40047 0 41538 0 692029 0 0 0 JOSEPH DAMOND THRU JAN 2022 DEPUTY CHIEF POLICY OFFICER AND EVP 53384 0 130000 0 416841 0 1030 0 4340 0 605595 0 0 0 RACHEL K KING PRES CEO EMERITUS BOARD MEM (SINCE NOV 2022) 240892 0 0 0 750 0 0 0 5929 0 247571 0 0 0 PART I, LINE 1A THE ORGANIZATION'S CEO WAS PERMITTED TO USE FIRST-CLASS FARES FOR BUSINESS TRAVEL PAID FOR BY THE ORGANIZATION. THE ORGANIZATION DID NOT TREAT FIRST-CLASS TRAVEL AS A TAXABLE FRINGE BENEFIT IN 2022. PART I, LINES 4A-B THE ORGANIZATION HAS A NONQUALIFIED DEFERRED COMPENSATION PLAN. UNDER THE TERMS OF THE PLAN, THE PARTICIPANTS ARE ENTITLED TO BENEFITS IF THEY REMAIN EMPLOYED BY THE ORGANIZATION UNTIL A PREDETERMINED TIME. THE PLAN IS INTENDED TO BE A NONQUALIFIED, UNFUNDED PROGRAM FOR THE BENEFIT OF A SELECT GROUP OF MANAGEMENT OR HIGHLY COMPENSATED EMPLOYEES OF BIO WITHIN THE MEANING OF ERISA. THE FOLLOWING CONTRIBUTIONS WERE MADE TO THE NONQUALIFIED DEFERRED COMPENSATION PLAN DURING 2022: MICHELLE MCMURRY-HEATH: $225,000 JOSEPH DAMOND RECEIVED A ONE-TIME SEVERANCE PAYMENT OF $416,541 UPON SEPARATION FROM SERVICE DURING THE TAX YEAR. FORM 990, PART VI, SECTION A, LINE 1A THE BOARD OF DIRECTORS SHALL DESIGNATE BY RESOLUTION AND WITH A QUORUM PRESENT, NOT MORE THAN TWENTY-THREE (23) DIRECTORS OF THE BOARD TO ACT AS AN EXECUTIVE COMMITTEE. THE EXECUTIVE COMMITTEE SHALL CONSIST OF THE SEVEN (7) ELECTED OFFICERS OF THE ORGANIZATION; THE IMMEDIATE PAST CHAIR OF THE ORGANIZATION; THE VICE CHAIRS OF EACH SECTION'S GOVERNING BOARD; AND THE BALANCE BEING AT-LARGE DIRECTORS FROM THE FULL BOARD. IF THE IMMEDIATE PAST CHAIR IS NO LONGER ELIGIBLE TO SERVE ON THE FULL BOARD, AN ADDITIONAL AT-LARGE DIRECTOR FROM THE FULL BOARD SHALL BE SELECTED FOR THE EXECUTIVE COMMITTEE. THE EXECUTIVE COMMITTEE SHALL HAVE, AND BE AUTHORIZED TO EXERCISE, ALL POWERS OF THE FULL BOARD, EXCEPT: (A) THE POWER TO ELECT OR REMOVE ELECTED OFFICERS OR DIRECTORS, TO CHANGE THE SIZE OF THE BOARD, TO CHANGE ELIGIBILITY, QUALIFICATIONS OR RIGHTS OF MEMBERSHIP, OR TO MAKE DETERMINATIONS AS TO DIRECTOR AND OFFICER COMPENSATION, WHERE APPLICABLE; AND (B) THE POWER TO AMEND THE ARTICLES OF INCORPORATION OR THE BYLAWS OF THE ORGANIZATION. FORM 990, PART VI, SECTION A, LINE 2 BOARD MEMBERS BRUCE COZADD AND RICHARD WINNINGHAM HAVE A BUSINESS RELATIONSHIP. FORM 990, PART VI, SECTION A, LINE 6 THE MEMBERS OF THE ORGANIZATION SHALL BE DIVIDED INTO FOUR CLASSES; CORE MEMBERS, ASSOCIATE MEMBERS, AFFILIATE MEMBERS, AND CENTER MEMBERS, DEFINED AS FOLLOWS: (A) CORE MEMBERS: ANY CORPORATION, PARTNERSHIP, ASSOCIATION, OR OTHER ENTITY ORGANIZED FOR PROFIT, A SUBSTANTIAL PERCENTAGE OF WHOSE BUSINESS ACTIVITIES INVOLVE BIOTECHNOLOGY, GENOMICS, BIOINFORMATICS OR RELATED NEW TECHNOLOGIES, IS ELIGIBLE FOR MEMBERSHIP. CORE MEMBERS ARE THOSE ENTITIES THAT UTILIZE BIOTECHNOLOGY, GENOMICS, BIOINFORMATICS OR OTHER RELATED NEW TECHNOLOGIES IN RESEARCH, DEVELOPMENT, TESTING, MANUFACTURING, OR SALES OF PRODUCT OR INFORMATION, AS WELL AS OTHER FIRMS THE BOARD SO CHARACTERIZES AND PLACES IN THIS CATEGORY. CORE MEMBERS SHALL BE GROUPED IN THE FOLLOWING SUBCATEGORIES: (I) EMERGING COMPANIES, WHICH ARE FIRMS THAT EMPLOY LESS THAN 350 PERSONS AND THAT DO NOT HAVE A THERAPEUTIC OR DIAGNOSTIC PRODUCT APPROVED FOR SALE IN THE U.S. MARKET; (II) ESTABLISHED FIRMS, WHICH ARE THOSE FIRMS THAT EMPLOY 350 OR MORE PERSONS OR THAT HAVE A THERAPEUTIC OR DIAGNOSTIC PRODUCT APPROVED FOR SALE IN THE U.S. MARKET; AND (III) LARGE FIRMS, WHICH ARE ESTABLISHED FIRMS THAT HAVE ANNUAL WORLDWIDE SALES OF BIOTECHNOLOGY PRODUCTS IN EXCESS OF $1.5 BILLION; AND (IV) NON-DOMESTIC COMPANIES, WHICH ARE CORE MEMBERS WITHOUT SIGNIFICANT OPERATIONS IN THE UNITED STATES OR SIGNIFICANT COLLABORATIONS WITH A U.S. ENTITY. (B) ASSOCIATE MEMBERS: ANY CORPORATION, PARTNERSHIP, ASSOCIATION, OR OTHER ENTITY ORGANIZED FOR PROFIT, A SUBSTANTIAL PORTION OF WHOSE ACTIVITIES INVOLVE PROVIDING SERVICES OR PRODUCTS OF BENEFIT TO COMPANIES WHOSE PRINCIPAL BUSINESS IS BIOTECHNOLOGY, IS ELIGIBLE FOR ASSOCIATE MEMBERSHIP. ASSOCIATE MEMBERS ARE THOSE COMMERCIAL ENTITIES WHICH DO NOT NECESSARILY UTILIZE BIOTECHNOLOGY; E.G. TECHNICAL SUPPORT, EQUIPMENT, CONSTRUCTION, ACCOUNTING, AND LAW FIRMS THAT SERVICE THE BIOTECHNOLOGY INDUSTRY, AS WELL AS OTHER FIRMS THAT THE BOARD CHARACTERIZES AND PLACES IN THIS CATEGORY. (C) AFFILIATE MEMBERS: ANY GOVERNMENTAL OR NONPROFIT ENTITY OR COUNTRY, STATE OR REGIONAL INDUSTRY, TRADE OR PROFESSIONAL ASSOCIATION WITH AN INTEREST IN, OR A MANDATE TO PROMOTE THE DEVELOPMENT OF, BIOTECHNOLOGY IS ELIGIBLE FOR AFFILIATE MEMBERSHIP. THERE SHALL BE NO SIZE TESTS APPLIED TO AFFILIATE MEMBER APPLICANTS. (D) CENTER MEMBERS: ANY INSTITUTION, NOT GENERALLY ELIGIBLE FOR CORE MEMBERSHIP THAT IS SPONSORED BY A STATE, REGION, OR ACADEMIC INSTITUTION AND WORKS IN SUPPORT OF COMMERCIAL BIOTECHNOLOGY MAY BE ELIGIBLE FOR CONSIDERATION AS A CENTER MEMBER. FORM 990, PART VI, SECTION A, LINE 7A AT ALL MEMBERSHIP MEETINGS OF THE ORGANIZATION, EACH CURRENT MEMBER SHALL HAVE ONE (1) VOTE AND MAY TAKE PART IN THE VOTING IN PERSON OR BY PROXY. FOR EACH SECTION IN WHICH THE MEMBER PARTICIPATES, EACH MEMBER SHALL HAVE THE RIGHT TO VOTE ON THE ELECTION OF DIRECTORS FOR THE SECTION GOVERNING BOARD, BUT SHALL HAVE NO OTHER VOTING RIGHTS EXCEPT ON MATTERS BROUGHT TO THE MEMBERSHIP BY ANY SUCH GOVERNING BOARD OR THE ORGANIZATION'S BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 AND RELATED SCHEDULES ARE PREPARED BY THE ORGANIZATION'S CERTIFIED PUBLIC ACCOUNTANTS WITH INFORMATION PROVIDED BY AND UNDER THE GUIDANCE OF THE CHIEF FINANCIAL OFFICER (CFO). THE CFO AND THE CONTROLLER THOROUGHLY REVIEW ALL CALCULATIONS AND SCHEDULES TO CONFIRM THEY REFLECT THE ACTUAL FINANCIAL RESULTS OF THE ORGANIZATION. THE COMPLETE FORM 990 IS THEN REVIEWED INTERNALLY BY THE CFO, AND CONTROLLER IN CONSULTATION WITH LEGAL COUNSEL AND, AS APPROPRIATE, FURTHER CONSULTATION WITH THE ORGANIZATION'S CERTIFIED PUBLIC ACCOUNTANTS. ALL REVIEWS ARE COMPLETED BEFORE THE FORM IS FILED WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO) TAKES SEVERAL STEPS TO ADDRESS COMPLIANCE BY KEY EMPLOYEES, OFFICERS AND DIRECTORS WITH ITS CONFLICTS OF INTEREST POLICY. BIO TRAINS ALL NEW EMPLOYEES AND DIRECTORS ON VARIOUS ASPECTS OF BIO'S COMPLIANCE PROGRAM, INCLUDING CONFLICTS OF INTEREST, AND BIO'S WRITTEN CONFLICTS OF INTEREST POLICY REQUIRES ALL EMPLOYEES TO DISCLOSE ANY OUTSIDE PERSONAL BUSINESS INTERESTS TO THEIR SUPERVISOR. BIO'S GENERAL COUNSEL REGULARLY ADVISES BIO'S EXECUTIVES AND SUPERVISORS ON SUCH MATTERS. BIO ALSO CONTRACTS WITH AN INDEPENDENT ORGANIZATION TO PROVIDE EMPLOYEES AND OTHERS WITH THE ABILITY TO FILE ANONYMOUS REPORTS CONCERNING THE VIOLATION OF ANY LAWS OR BIO POLICIES, INCLUDING ALLEGATIONS OF POTENTIAL CONFLICTS OF INTEREST, AND BIO HAS A PROCESS IN PLACE TO FOLLOW UP ON ANY SUCH COMPLAINTS IN A TIMELY AND THOROUGH MANNER. FURTHER, BIO UNDERTAKES A QUESTIONNAIRE SENT TO EACH DIRECTOR ON ITS BOARD OF DIRECTORS SEEKING DISCLOSURE OF ANY POTENTIAL CONFLICTS OF INTERESTS THEY MAY HAVE, OR THEIR FAMILY MEMBERS MAY HAVE, ASSOCIATED WITH BUSINESSES OR ORGANIZATIONS THAT DO BUSINESS WITH BIO. POTENTIAL CONFLICTS ARE MONITORED AND REVIEWED AT THE MANAGEMENT AND SENIOR MANAGEMENT LEVEL OF THE ORGANIZATION, AND DEPENDING ON THE CONFLICT, DETERMINATIONS MAY BE MADE AT THE BOARD OR SENIOR MANAGEMENT LEVEL. A CONFLICT AT THE BOARD LEVEL WILL NORMALLY RESULT IN RECUSAL OF THE INDIVIDUAL FROM PARTICIPATION OR ACTIVITIES WITH RESPECT TO THE RELEVANT SUBJECT MATTER. AT THE STAFF LEVEL, THE APPLICABLE BIO SUPERVISOR IS INFORMED OF THE POTENTIAL CONFLICT AND IS REQUIRED TO TAKE ALL APPROPRIATE STEPS TO ENSURE THAT THE INDIVIDUAL DOES NOT PARTICIPATE IN, OR RECEIVE CONFIDENTIAL INFORMATION RELATING TO, ANY BIO ACTIVITY RELATED TO THE SUBJECT MATTER OF THE CONFLICT, UP TO AND INCLUDING, WHERE APPROPRIATE, TERMINATION OF SUCH EMPLOYEE. FORM 990, PART VI, SECTION B, LINE 15 FOR 2022, THE PRESIDENT AND CHIEF EXECUTIVE OFFICER (CEO) OF BIO (BIOTECHNOLOGY INNOVATION ORGANIZATION 52-1224577) WAS COMPENSATED PER THE TERMS OF A MULTI-YEAR CONTRACT THAT WAS DETERMINED WITH INDEPENDENT REVIEW, COMPARABILITY DATA, AND CONTEMPORANEOUS SUBSTANTIATION OF THE DELIBERATION AND DECISION, AS INDICATED IN PRIOR FORM 990 SUBMISSIONS. IN ADDITION, BASED ON THE EXECUTIVE COMMITTEE'S EVALUATION OF THE PRESIDENT AND CEO'S PERFORMANCE FOR 2022, THE COMMITTEE DETERMINED THE APPROPRIATE AMOUNT FOR THE DISCRETIONARY COMPONENT OF COMPENSATION FOR THAT YEAR, IN ACCORDANCE WITH THE RELEVANT PROVISION OF THE EXECUTIVE AGREEMENT. WHEN DETERMINING THE COMPENSATION OF THE BIO PRESIDENT & CEO, BIO HAS USED AN EXPERT OUTSIDE CONSULTANT TO BENCHMARK COMPENSATION. COMPENSATION OFTEN INCLUDES MORE THAN JUST SALARY AND BONUS, AND TO THIS END, BIO USES AN EXPERT OUTSIDE LEGAL COUNSEL WHO HAS EXTENSIVE EXPERIENCE IN NEGOTIATING THE TERMS OF CONTRACTS FOR THE PRESIDENT & CEO OF TRADE ASSOCIATIONS IN DC OF SIMILAR SIZE TO BIO. DECISIONS REGARDING THE COMPENSATION FOR OFFICERS AND KEY EMPLOYEES OF THE ORGANIZATION ARE NEGOTIATED INDIVIDUALLY AND ARE PERFORMANCE-BASED, IN ACCORDANCE WITH AN ANNUAL WRITTEN EVALUATION PROCESS THAT HAS BEEN ESTABLISHED FOR ALL EMPLOYEES OF THE ORGANIZATION. AN INDEPENDENT CONSULTANT PROVIDES COMPARATIVE BENCHMARKING SERVICES FOR SENIOR MANAGEMENT POSITIONS, AND OTHER INFORMATION ON COMPENSATION ISSUES, TRENDS, POLICIES, AND BEST PRACTICES FOR USE BY THE ORGANIZATION. THE ORGANIZATION ALSO HAS AN ESTABLISHED COMPENSATION POLICY FOR ALL OF ITS EMPLOYEES, WHICH SETS FORTH THE GENERAL PARAMETERS GOVERNING BIO'S COMPENSATION PRACTICES. THE PROCESS DESCRIBED HERE WAS LAST COMPLETED IN 2022. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION DOES NOT MAKE ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC. FORM 990, PART VII, SECTION A, LINE 1: MICHELLE MCMURRY-HEATH STEPPED DOWN AS PRESIDENT AND CEO IN OCTOBER OF 2022. AT THAT TIME, SHE TRANSITIONED FROM CEO TO A NON-OFFICER EMPLOYEE PROVIDING CONSULTING TO THE BOARD UNTIL FEBRUARY OF 2023.